Journal of Inflammation Research (Jul 2022)
The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
Abstract
Jiwen Fan,1 Meng Ren,2 Binay Kumar Adhikari,3 Haodong Wang,1 Yuquan He1 1Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, People’s Republic of China; 2Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, People’s Republic of China; 3Department of Cardiology, Nepal Armed Police Force (APF) Hospital, Kathmandu, NepalCorrespondence: Yuquan He, Department of Cardiology, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Road, Changchun, People’s Republic of China, Tel +86 15604411532, Email [email protected]: Cardiac fibrosis often has adverse cardiovascular effects, including heart failure, sudden death, and malignant arrhythmias. However, there is no targeted therapy for cardiac fibrosis. Inflammation is known to play a crucial role in the disorder, and the NLR pyrin domain-containing-3 (NLRP3) inflammasome is closely associated with innate immunity. Therefore, further understanding the pathophysiological role of the inflammasome in cardiac fibrosis may provide novel strategies for the prevention and treatment of the disorder. The aim of this review was to summarize the present knowledge of NLRP3 inflammasome-related mechanisms underlying cardiac fibrosis and to suggest potential targeted therapy that could be used to treat the condition.Keywords: NLRP3 inflammasome, cardiac fibrosis, AIM2, ASC, caspase-1
